In a report released today, Leland Gershell from Oppenheimer maintained a Hold rating on Alnylam Pharma (ALNY – Research Report). The company’s shares closed yesterday at $266.59.
According to TipRanks, Gershell is a 4-star analyst with an average return of 4.2% and a 37.73% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Capricor Therapeutics, Alnylam Pharma, and Soleno Therapeutics.
In addition to Oppenheimer, Alnylam Pharma also received a Hold from Wells Fargo’s Tiago Fauth in a report issued yesterday. However, today, TD Cowen assigned a Buy rating to Alnylam Pharma (NASDAQ: ALNY).
The company has a one-year high of $304.39 and a one-year low of $141.98. Currently, Alnylam Pharma has an average volume of 834.2K.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Alnylam Pharma (ALNY) Company Description:
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
Read More on ALNY:
- Alnylam price target raised to $384 from $366 at Canaccord
- U.S. drugmakers shifting away from Chinese supply-chain partners, WSJ says
- Alnylam price target raised to $329 from $295 at Barclays
- Alnylam Pharmaceuticals Reports Mixed Quarterly Earnings
- Alnylam sees FY24 combined net product revenues $1.58B – $1.65B
